Cat Jennings
@bsc_vascular
Followers
156
Following
106
Media
60
Statuses
117
President, Peripheral Vascular at Boston Scientific, Peripheral Interventions @bsc_pi
Maple Grove, MN
Joined April 2023
Dr. Ramzan Zakir shows how the Ranger Monorail DCB is advancing #PAD treatment. Its 200cm platform delivers pushability, stability & access, supporting broader procedural options including radial access, & improved patient throughput. @rzakir12 Full video: https://t.co/e7lFiosdTA
2
2
7
Be part of the conversation shaping the future of #pulmonaryembolism care. Join #PE experts as they share the latest clinical insights & perspectives on upcoming randomized controlled trials that are expected to transform PE treatment. 👉 Register today: https://t.co/7joQ3lb6LL
0
5
3
LIVE @ #VIVA25| Redefining Vascular Intervention: #SEISMIQ #IVL & #DrugElution Strategies for PAD | How SEISMIQ IVL and DE strategies are redefining #PAD treatment through real cases, data, and discussion. The next generation of IVL starts here. @VIVAPhysicians
0
2
6
Congrats to our case competition winner, @atfisherMD! ⭐️ She presented a complex BTK CLTI case with a long CTO, utilizing #IVL for vessel prep and #Eluvia for limb salvage and wound healing. @StanfordVasc #VIVA25 @VIVAPhysicians
0
1
5
LIVE @ #VIVA25 | Trainees in Action: Real-World Vascular Case Competition | The next generation of vascular innovators is taking the stage. Trainees showcase real-world cases, tackle tough decisions, and compete in a dynamic, interactive format. @VIVAPhysicians
1
3
7
#VIVA25: Meghan Dermody shares one-year outcomes from the ROADSTER 3 study of #TCAR in standard-risk patients @VIVAPhysicians
0
4
5
Presented at #VIVA25 | #ROADSTER 3: 1-year data from the first-ever independently adjudicated, prospective study of #TCAR performed in standard surgical-risk patients with the #ENROUTE TSS & NPS is safe, durable, & effective. #EvidenceBasedMedicine @VIVAPhysicians
0
2
3
LIVE @ #TheVEINS25 | Smooth Sailing: Navigating Varithena in Practice | @drksterling and Raghu Kolluri, MD are diving into real-world #Varithena cases, practical tips, and reimbursement insights to keep your journey on course.
0
1
4
Don’t miss the shift…visit the Boston Scientific suite at #VIVA25 to see the SEISMIQ difference 🔍 Learn more: https://t.co/aYXg6bH4Co
#TheShiftIsSEISMIQ #IVLtherapy #ComingSoon
0
3
4
LIVE @ #TheVEINS25 | Be Ready for What’s Next in PE | Data-driven insights are in focus as top experts share the latest evidence and practical pearls in #pulmonaryembolism management - helping you stay ahead of what’s next💡
0
1
4
Gearing up for #VEINS25 & #VIVA25? 📅 Join us for these exciting events, symposia, and hands-on experiences. You won’t want to miss it! @VIVAPhysicians
0
2
4
At our recent Advanced Vascular Master Class, multi-specialty physicians deepened their expertise in #PE, #PAD & #CAD through interactive cases, data review, & hands-on learning. A big thank you to our program director @docmrjaff, faculty, & attendees for making this a success!
0
0
1
Join us for this engaging webinar to help navigate the complexities of endovascular PAD & CLI interventions, including: 🔹Clinical data reinforcing Eluvia DES effectiveness 🔹Case insights on complex lesions 🔹+ more 👉 Register: https://t.co/bupNja9pKm
@bsc_pi @bsc_vascular
0
5
9
🔍New to #Varithena? Interested in a practical refresher? Join us at #VSS2025 for a foundational overview of the Varithena procedure—including supporting clinical data, a step-by-step walkthrough of the treatment process, & real-world cases from expert faculty members @SVM_tweets
0
0
0
🌍 Global Expert Perspectives on a Pivotal Year for #PE Join global thought leaders from diverse medical specialties at #PERT2025 as they reflect on key lessons in #pulmonaryembolism management and share what’s ahead in this rapidly evolving field.
0
0
3
🔍Join us at #NYEVS2025 | Experts will review preliminary data from the #SEISMIQ trials, lead an interactive discussion, and share key takeaways + future milestones. #ClinicalTrials #EvidenceBasedMedicine
0
1
5
We’re excited to invite you to an upcoming VIVA webinar on September 3. Join us to explore the latest drug-elution data and hear from leading experts. Register today: https://t.co/6G0IohEOWR
#EluviaDES #RangerDCB #DrugElution
🚨PAD data presentations, directly from Europe. Join us September 3 for an in-depth review of the most important drug elution results from LINC & Charing Cross 2025 including a new meta-analysis, the Elegance Registry, and SPORTS Trial. Wednesday, September 3 | 8pm ET | 5pm PT
0
2
8
Successful Radial-First Treatment of Complex SFA Disease Using #RangerDCB 200cm with Dr. @rzakir12!
76M w/ DM, HTN, CAD (post-PCI), ex-smoker & Rutherford 3 claudication. #RadialAccess angiography → severe calcified SFA Tx: Orbital atherectomy + PTA w/ #RangerDCB 200cm ✅ Minimal residual stenosis ✅ Excellent runoff via dominant peroneal Radial-first & device-enabled.
0
1
9
Big News! The 544th—and final—patient has been enrolled in #HIPEITHO, a landmark RCT comparing EKOS + anticoagulation vs. anticoagulation alone in intermediate-high risk #PE. Thank you to our investigators, @PERTConsortium & @UnimedizinMainz. Learn more: https://t.co/u5SkH7GUiS
1
15
58